A Multicentre, Randomised, Double-blind, Placebo-controlled Phase III Trial Investigating the Efficacy and Safety of FE 999901 Vaginal Insert in Pregnant Women at Term (41 Weeks of Gestation) Requiring Cervical Ripening
Phase of Trial: Phase III
Latest Information Update: 28 Sep 2018
At a glance
- Drugs Dinoprostone (Primary)
- Indications Labour induction
- Focus Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 21 Sep 2018 Status changed from recruiting to completed.
- 11 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Sep 2018.
- 11 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2018.